Search

Displaying results 5251 - 5260 of 7498 in total
  1. Drug

    TAS-102

    go.drugbank.com/drugs/DB08937
    Investigational

    Trifluridine inhibits tumor growth by being incorporated into DNA during DNA synthesis. Tipiracil prevents trifluridine from being broken down when taken orally.

  2. Drug

    Candoxatrilat

    go.drugbank.com/drugs/DB11623
    Experimental

    A dicarboxylic acid monoamide obtained by formal condensation between the amino group of cis-4-aminocyclohexanecarboxylic acid and the cyclopentanecarboxylic acid group of 1-[(2S)-2-carboxy-3-(2-methoxyethoxy

  3. Drug

    Lifitegrast

    go.drugbank.com/drugs/DB11611
    ApprovedInvestigational

    It has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast onset of action and well tolerated profile in both local and systemic setting [A18805].

  4. Drug

    PMI-001

    go.drugbank.com/drugs/DB05730
    Experimental

    PMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics Inc.

  5. Drug

    Enlonstobart

    go.drugbank.com/drugs/DB21890
    Investigational

    [A274486] It targets the programmed cell death protein 1 (PD-1), is being developed by the CSPC Pharmaceutical Group for the treatment of advanced cervical cancer and other solid tumours.

  6. Drug

    Avena sativa flowering top

    go.drugbank.com/drugs/DB14253
    Approved

    It is not an approved drug.

  7. Drug

    Adafosbuvir

    go.drugbank.com/drugs/DB14906
    Investigational

    Adafosbuvir is under investigation in clinical trial NCT02894905 (A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335).

  8. Drug

    Bixalomer

    go.drugbank.com/drugs/DB15200
    Investigational

    Bixalomer is under investigation in clinical trial NCT01115985 (A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Atorvastatin in Healthy Volunteers).

  9. Drug

    Artesunate

    go.drugbank.com/drugs/DB09274
    ApprovedInvestigational

    [A203948] Artesunate was granted FDA approval on 26 May 2020.[L14099]

  10. Drug

    Alferminogene tadenovec

    go.drugbank.com/drugs/DB05306
    Investigational

    Alferminogene tadenovec, Cardium’s lead product candidate, is being developed for the potential treatment of myocardial ischemia that gives rise to angina symptoms associated with coronary heart disease … Alferminogene tadenovec represents a new therapeutic class of biologics designed to promote angiogenesis and thereby improve blood flow following a one-time intracoronary administration from a standard